Kalbe Farma Provides Earnings Results for the Fiscal Year 2016, Provides Earnings Guidance for the Year 2017
February 14, 2017 at 10:21 am EST
Share
Kalbe Farma reported earnings results for the fiscal year 2016. For the year, the company posted a 8.3% year-on-year rise in fiscal year 2016 net sales. Net sales for the 12 months to 31 December 2016 reached IDR 19.367 trillion (USD 1.5 billion) from IDR 17.887 trillion a year earlier, driven mostly by stronger sales volume, better purchasing power, and controlled inflation rate. Operating profit climbed by 15.6% year-on-year to IDR 3.1 trillion in fiscal year 2016, equivalent to a 15.8% ratio of net sales, and net income increased by 13.5% year-on-year to IDR 2.3 trillion.
Kalbe Farma (Indonesia) is targeting sales growth of 8-9% in 2017, driven by 10-15 new products across different business divisions, including pharmaceuticals, consumer health, and nutrition. The company is also forecasting an operating profit margin of 14.5-15.5%, and has set aside a capital expenditure budget of IDR 1.2 trillion to expand manufacturing capacity.
PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.